christopher ritchlin

Has grant

Professor/ Division Chief

University of Rochester Medical Center

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Christopher Ritchlin is a Professor and Division Chief at the University of Rochester Medical Center in the United States. His research primarily focuses on psoriatic arthritis, including the efficacy of biologic treatments and the assessment of disease progression. Recent articles highlight his work on various therapeutic interventions and the underlying immune profiles in psoriatic disease.

Recent Grants

Grant: Close

Cutaneous RANKL expression and subclinical joint inflammation in psoriasis

Open Date: 2017-08-01

Close Date: 2018-07-31

Grant: Close

DC-STAMP: Regulator of Osteoclastogenesis and Response Marker in PsA

Open Date: 2016-03-01

Close Date: 2021-01-31

Grant: Close

CIHR Team in Psoriasis and Psoriatic Arthritis

Open Date: 2007-07-01

Close Date: 2012-06-30

Articles (21)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Collaborators (21)

Dafna D. Gladman

University of Toronto

CANADA

christopher ritchlin

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (21)

Imaging Mass Cytometry in Psoriatic Disease Reveals Immune Profile Heterogeneity in Skin and Synovial Tissue

Guselkumab Efficacy in Biologic-Naïve Participants with Psoriatic Arthritis and Severe Disease Activity: Post Hoc Analysis of a Phase 3 Study

Inhibition of structural damage progression with the selective interleukin-23 inhibitor guselkumab in participants with active PsA: results through week 24 of the phase 3b, randomised, double-blind, placebo-controlled APEX study

Correction: Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies

Psoriatic arthritis subtypes are phenocopied in humanized mice

Breakout Session and Report Back: Collaboration of Rheumatologists and Dermatologists for the Care of Patients With Psoriatic Disease

GRAPPA 2023 Collaborative Research Network Meeting

Phase 2 Trial of Deucravacitinib in Psoriatic Arthritis: Biomarkers Associated With Disease Activity, Pharmacodynamics, and Clinical Responses

Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies

Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study

Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL

Guselkumab Modulates Differentially Expressed Genes in Blood of Patients With Psoriatic Arthritis: Results from Two Phase 3, Randomized, Placebo‐Controlled Trials

Expert Perspective: Management of the Psoriatic Arthritis Patient After Failure of One Tumor Necrosis Factor Inhibitor

Dysregulation of Bile Acids, Lipids, and Nucleotides in Psoriatic Arthritis Revealed by Unbiased Profiling of Serum Metabolites

Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo‐Controlled DISCOVER‐1 Study

Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study

Derivation of a multivariable psoriatic arthritis risk estimation tool (PRESTO): a step towards prevention

The Enigmas of Lymphatic Muscle Cells: Where Do They Come From, How Are They Maintained, and Can They Regenerate?

The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial

Thy-1 plays a pathogenic role and is a potential biomarker for skin fibrosis in scleroderma

Identification and Characterization of a High‐Need, High‐Cost Group Among Hospitalized Patients With Systemic Lupus Erythematosus

Collaborators (21)

Dafna D. Gladman

Stephen R. Pennington

Atul Deodhar

Jessica Widdifield

Lihi Eder

Arthur Kavanaugh

Ying Ying Leung

Laure Gossec

Stefan Siebert

Robert Landewé

Roberta Goncalves Marangoni

Hartland Jackson

Vinod Chandran

Samuel T. Hwang

Vincent Piguet

Edward M. Schwarz

Javier Rangel-Moreno

Maria de la luz Garcia-Hernandez

Alexis Ogdie

Laura Coates

H. Mark Kenney

Make your next move.